Woodline Partners LP Insmed Inc Transaction History

Woodline Partners LP

$19.5 Billion
Q3 2025

A detailed history of Woodline Partners LP transactions in Insmed Inc stock. As of the latest transaction made, Woodline Partners LP holds 126,262 shares of INSM stock, worth $24.4 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

126,262

Previous 248,921 49.28%

Holding current value

$24.4 Million

Previous $25.1 Million 27.42%

% of portfolio

0.09%

Previous 0.14%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$96.14 - $147.2 $11.8 Million - $18.1 Million	-122,659 Reduced 49.28%	126,262 $18.2 Million
Q2 2025 Aug 14, 2025	BUY	$64.81 - $105.9 $9,786 - $15,990	151 Added 0.06%	248,921 $25.1 Million
Q1 2025 May 15, 2025	BUY	$65.25 - $83.83 $5.65 Million - $7.25 Million	86,540 Added 53.34%	248,770 $19 Million
Q4 2024 Feb 14, 2025	SELL	$66.29 - $76.63 $3.59 Million - $4.15 Million	-54,149 Reduced 25.03%	162,230 $11.2 Million
Q3 2024 Nov 14, 2024	BUY	$62.0 - $79.01 $3.8 Million - $4.84 Million	61,224 Added 39.46%	216,379 $15.8 Million

Q2 2024 Aug 14, 2024	BUY	$22.0 - $69.71 $3.41 Million - $10.8 Million	155,155 New	155,155 $10.4 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $3.23 Million - $4.4 Million	190,000 New	190,000 $3.8 Million
Q1 2022 May 16, 2022	SELL	$20.42 - $28.13 $2.05 Million - $2.82 Million	-100,185 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$25.89 - $33.45 $2.95 Million - $3.81 Million	-113,783 Reduced 53.18%	100,185 $2.73 Million
Q3 2021 Nov 15, 2021	SELL	$22.46 - $29.47 $4.1 Million - $5.38 Million	-182,583 Reduced 46.04%	213,968 $5.89 Million
Q2 2021 Aug 16, 2021	BUY	$24.17 - $36.01 $9.58 Million - $14.3 Million	396,551 New	396,551 $11.3 Million

Others Institutions Holding INSM

# of Institutions

643

Shares Held

208M

Call Options Held

3.83M

Put Options Held

4.26M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $26.2B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Insmed Inc Transaction History